Replies to post #89005 on Amarin Corp Plc (AMRN)

[HDGabor]

P-

I'm not at all sure what you are arguing about

About "The point is if Vas was deemed *better* than Lovaza (or its generics) then it would be higher tiered than Lov.", since it isn't how the system works. (Maybe it helps: What Is a Health Insurer's Drug Formulary and Tier Pricing?)

And btw, they both require prior auth in that plan.

??? Are you sure ...? Check it again: #88919 (O3 - Tier 3 /PAR; MO, V - Tier 4 / MO)

It covers generic L. And there is no PBM formulary with Vas higher tiered than L or L generic. Let alone "a lot of" them.

Like: 2016 Coventry Prescription Drug List
• omega-3 acid ethyl esters 1 gram capsule - Tier 1
• Vascepa 1 gram capsule - Tier 2
• Lovaza 1 gram capsule - Tier 3
Could you describe the difference between omega-3 acid ethyl esters and Lovaza? Why generic is better than brand ...? It should be (acc. to you) since gL is T1, meanwhile L is T3 ... or how about it: Express Scripts Medicare (PDP) 2016 Formulary (List of Covered Drugs)... V is Tier 3, gL and L not covered ... or 2016 Express Scripts National Preferred Formulary ...

Okay so lots of patients with 150 - 200 TG counts and one other risk factor were randomized. Got it.

Not exactly. 38% (lots of?) was between 150-202, but we do not know the mean. (The mean of the 8,000 will be definitely above and not below 200 (as you claimed) ... just a reminder about the starting point ...)
70% is CV Risk Category 1 (patients with established CVD defined in the inclusion criteria. Patients with diabetes and established CVD are included in this category.) and 30% is CV Risk Category 2 (patients with diabetes and at least one additional risk factor for CVD, but no established CVD.)
Protocol

Wrt baseline EPA levels and ANCHOR or MARINE vs R-IT, do you think control in R-IT will have baseline closer to MAR or ANCH? And why? What would you guess it will be?

Sorry, my fault, I wasn't careful (took together / mixed with the previous paragraph) ... but I am relaxed and not worry.
- closer to / similar to ANCHOR
- as more or less the same population
- +10%/-10-20% vs ANCHOR

Their lipids will remain blinded to them and their primary care doc?

VuBru could give a more educated answer (if he want), however do you think
- everybody has a primary care doc? Especially ex-US enrollees.
- wealthy, educated, etc are the most common or not? Unless clinical trial is a new hobby / trend among them I do not think.
But never mind ... If this is so common, drop-out is high, why the number wasn't increased? Please note: they made a check approximately 3- to 6-months prior to the projected enrollment of the 7990th patient.

Best,
G

[drrc1949]

Complete waste of time.....Pyrogordia has an agenda outside of the interests of Amarin or shareholders. He needs to be ignored.